

JCS94 U.S. PTO

**UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)***(Only for new nonprovisional applications under 37 CFR 1.53(b))*Docket No.
BSI-212Total Pages in this Submission
125**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

BIFURCATED ENDOLUMINAL PROSTHESIS

and invented by:

George Goicoechea; John Hudson; and Andrew H. CraggJCS94 U.S. PTO
09/387696
08/31/99If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☒ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: 08/960,282

Which is a:

☒ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: 08/463,987

Which is a:

☐ **Continuation** ☒ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: 08/317,763

Which is a: Continuation-in-part (CIP) of prior application No: 08/312,881

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 68 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☒ Cross References to Related Applications *(if applicable)*
 - c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
 - d. ☐ Reference to Microfiche Appendix *(if applicable)*
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☒ Brief Description of the Drawings *(if drawings filed)*
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
BSI-212

Total Pages in this Submission

Application Elements (Continued)

3. ☒ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☒ Formal Number of Sheets 23
- b. ☐ Informal Number of Sheets _____
4. ☒ Oath or Declaration
- a. ☐ Newly executed (original or copy) ☐ Unexecuted
- b. ☒ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☒ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied
under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy (identical to computer copy)
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (Specify Label No.): EL370858037US

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
BSI-212

Total Pages in this Submission

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. ☒ Additional Enclosures (please identify below):

U.S. Patent No. 5,800,515


Deletion of Inventors, 1.63(d)(2)

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	8	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	3	- 3 =	0	x \$78.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$760.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$760.00


- ☒ A check in the amount of \$760.00 to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 18-0350 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).


Signature

Paul F. Prestia, Reg. No. 23,031
Joshua L. Cohen, Reg. No. 38,040
Ratner & Prestia
Suite 301, One Westlakes, Berwyn
P.O. Box 980
Valley Forge, PA 19482-0980
Tel: (610) 407-0700

Dated: August 31, 1999

c:

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)			Docket No.
Applicant(s): George Goicoechea et al.			BSI-212
Serial No. To Be Assigned	Filing Date Herewith	Examiner To Be Assigned	Group Art Unit To Be Assigned
Invention: BIFURCATED ENDOLUMINAL PROSTHESIS			
<p>Transmittal Letter (Dup.); Specification and Claims (68 pages); (23) Sheets of Formal Drawings; Declaration/Power of Attorney (copy); Deletion of Inventors (1 page); Preliminary Amendment (5 pages);</p> <p>I hereby certify that this _____ (Identify type of correspondence) copy of U.S. Patent No. 5,800,515; check is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231</p> <p>on <u>August 31, 1999</u> (Date)</p> <div><div>Kathleen Libby (Typed or Printed Name of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence) EL370858037US (Express Mail Mailing Label Number)</div></div>			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: George Goicoechea et al. : Art Unit: unknown
Serial No.: To Be Assigned : Examiner: unknown
Filed: Herewith
For: BIFURCATED ENDOLUMINAL
PROSTHESIS

CONTINUATION APPLICATION OF:

Applicants: George Goicoechea et al. : Art Unit: 3738
Serial No.: 08/960,282 : Examiner: M. Milano
Filed: October 29, 1997
For: BIFURCATED ENDOLUMINAL
PROSTHESIS

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R :

Prior to examination, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please replace the first paragraph of the specification with the following:

This application is a continuation of Application Serial No. 08/960,282, filed October 29, 1997 (pending), which is a continuation of Application Serial No. 08/463,987, filed June 5, 1995 (pending), which is a division of Application Serial No. 08/317,763, filed October 4, 1994 (now U.S. Patent No. 5,609,627), which is a continuation-in-part of Application Serial No. 08/312,881, filed September 27, 1994 (pending). This application is also a continuation-in-part of Application Serial No. 08/312,881.

IN THE CLAIMS:

Please cancel claims 1-53, without prejudice or disclaimer of the subject matter thereof.

Please add the following new claims 54-61:

1 54. (Newly Added) A generally tubular prosthesis for implantation in a
2 human or animal duct to ensure a passageway in said duct, said prosthesis having a
3 tubular surface and a tube axis and being generally axially subdivided into two or
4 more circumferentially oriented hoop-like tubular portions, said prosthesis
5 comprising:

6 a plurality of discrete structural wires or filaments joined together to
7 form said prosthesis, said wires or filaments each having one or more corrugated
8 portions and at least some of said wires or filaments having one or more generally
9 straightened extension portions;

10 wherein said hoop-like tubular portions are formed from the corrugated
11 portions of two or more of said wires or filaments; and

12 wherein said extension portions extend between and connect
13 consecutive ones of said hoop-like tubular portions.

1 55. (Newly Added) The prosthesis of claim 54, wherein said corrugations
2 comprise zig-zags having V-shaped apices connected by generally straight
3 intermediate portions.

1 56. (Newly Added) The prosthesis of claim 54, wherein at least some of
2 said extension portions extending between and connecting consecutive ones of
3 said hoop-like tubular portions are oriented skew relative to the tubular axis.

1 57. (Newly Added) The prosthesis of claim 54, wherein said tubular
2 portions are arranged generally adjacent to each other.

1 58. (Newly Added) The prosthesis of claim 54, wherein said prosthesis is
2 a forked prosthesis comprising a generally tubular main branch and at least two
3 secondary branches extending from said main branch.

1 59. (Newly Added) The prosthesis of claim 54, wherein consecutive ones
2 of said hoop-like tubular portions are also connected at a point circumferentially
3 displaced from said extension portion.

1 60. (Newly Added) A generally tubular prosthesis for implantation in a
2 human or animal duct to ensure a passageway in said duct, said prosthesis having a
3 tubular surface and a tube axis and being generally axially subdivided into two or
4 more circumferentially oriented hoop-like tubular portions, said prosthesis
5 comprising:

6 a wire or filament having one or more corrugated portions and one or
7 more generally straightened extension portions;

8 wherein said hoop-like tubular portions are formed from the corrugated
9 portions of two or more of said wires or filaments; and

10 wherein said extension portions extend in a helical path between and
11 connect consecutive hoop-like tubular portions.

1 61. (Newly Added) An endoluminal stent comprising:

2 a plurality of hoops axially displaced in a tubular configuration along a
3 common axis;

4 each of said hoops comprising a plurality of sinuous or zig-zag
5 segments having apices in a plane substantially perpendicular to the longitudinal
6 axis of the stent; and

7 adjacent hoops being connected by a connecting segment that extends
8 along a helical path from a sinuous or zig-zag segment of one of said adjacent
9 hoops to a sinuous or zig-zag segment of the other one of said adjacent hoops.

REMARKS

Applicants have filed this continuation application to pursue the above claims, which are directed to exemplary features of a prosthesis or stent. Claims 54, 55, 56, 57, 58, and 60 are substantially copied from U.S. Patent No. 5,800,515, which issued to Nadal et al. on September 1, 1998. A copy of the Nadal patent is submitted herewith for the Examiner's convenience.

Claim 54 recites a prosthesis including a plurality of discrete structural wires or filaments joined together to form the prosthesis, the wires or filaments each having one or more corrugated portions and at least some of the wires or filaments having one or more generally straightened extension portions. Hoop-like tubular portions of the prosthesis are formed from the corrugated portions of two or more of the wires or filaments. Also, the extension portions extend between and connect consecutive ones of the hoop-like tubular portions.


As recited in claim 55, the corrugations can comprise zig-zags having V-shaped apices connected by generally straight intermediate portions. As recited in claim 56, at least some of the extension portions extending between and connecting consecutive ones of the hoop-like tubular portions can be oriented skew relative to the tubular axis. As recited in claim 57, the tubular portions can be arranged generally adjacent to each other. As recited in claim 58, the prosthesis can be a forked prosthesis comprising a generally tubular main branch and at least two secondary branches extending from the main branch. As recited in claim 59, consecutive hoop-like tubular portions can also be connected at a point circumferentially displaced from the extension portion.

Claim 60 recites a prosthesis including a wire or filament having one or more corrugated portions and one or more generally straightened extension portions. Hoop-like tubular portions of the prosthesis are formed from the corrugated portions of two or more of the wires or filaments, and the extension portions extend in a helical path between and connect consecutive hoop-like tubular portions.

Claim 61 recites an endoluminal stent including a plurality of hoops axially displaced in a tubular configuration along a common axis. Each of the hoops comprises a plurality of sinuous or zig-zag segments having apices in a plane substantially perpendicular to the longitudinal axis of the stent. Adjacent hoops are connected by a connecting segment that extends along a helical path from a sinuous or zig-zag segment of one of the adjacent hoops to a sinuous or zig-zag segment of the other one of the adjacent hoops.

Support for claims 54-61 can be found in Applicants' Figs. 1A, 1B, 2A, 2B, 3, and 4A-4F. Support is also found in Applicants' specification at page 23, line 11 through page 27, line 2. Additional support for claims 54-61 can be found elsewhere throughout Applicants' specification and figures.

Respectfully Submitted,



Paul F. Prestia, Reg. No. 23,031
Joshua L. Cohen, Reg. No. 38,040
Attorneys for Applicants

Dated: August 31, 1999
Suite 301
One Westlakes, Berwyn
P.O. Box 980
Valley Forge, PA 19482-0980
(610) 407-0700

The Assistant Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. 18-0350 of any fees associated with this communication.

EXPRESS MAIL Mailing Label Number: EL370858037US

Date of Deposit: August 31, 1999

I hereby certify that this paper and fee are being deposited, under 37 C.F.R. § 1.10 and with sufficient postage, using the "Express Mail Post Office to Addressee" service of the United States Postal Service on the date indicated above and that the deposit is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Kathleen Libby

BIFURCATED ENDOLUMINAL PROSTHESIS

This is a continuation-in-part application of the application of common assignment herewith of inventors George Goicoechea, Claude Mialhe, John Hudson and Andrew Cragg, entitled BIFURCATED ENDOLUMINAL PROSTHESIS, filed on September 27, 1994, for which application a serial number had not yet been assigned as of the date of filing this continuation-in-part application.

BACKGROUND OF THE INVENTION

10

The present invention relates to a bifurcated endoluminal prosthesis for use in a bifurcated blood vessel such, for example, as the infrarenal portion of a mammalian aortic artery where it bifurcates to the common iliac arteries. The present invention also embraces a

stent connecting means for connecting a stent (e.g. a stent which forms part of an endoluminal prosthesis) to another stent, as well as apparatus and method for introducing prostheses to the vasculature and methods of treating angeological diseases.

A stent is used to provide a prosthetic intraluminal wall e.g. in the case of a stenosis to provide an unobstructed conduit for blood in the area of the stenosis. An endoluminal prosthesis comprises a stent which carries a prosthetic graft layer of fabric and is used e.g. to treat an aneurysm by removing the pressure on a weakened part of an artery so as to reduce the risk of embolism, or of the natural artery wall bursting. Typically, a stent or endoluminal prosthesis is implanted in a blood vessel at the site of a stenosis or aneurysm by so-called "minimally invasive techniques" in which the stent is compressed radially inwards and is delivered by a catheter to the site where it is required through the patient's skin or by a "cut down" technique in which the blood vessel concerned is exposed by minor surgical means. When the stent is positioned at the correct location, the catheter is withdrawn and the stent is caused or allowed to re-expand to a predetermined diameter in the vessel.

U.S. Patent 4,886,062 discloses a vascular stent which comprises a length of sinuous or "zig-zag" wire formed into a helix; the helix defines a generally cylindrical wall which, in use, constitutes a prosthetic

intraluminal wall. The sinuous configuration of the wire permits radial expansion and compression of the stent; US-A-4886062 discloses that the stent can be delivered percutaneously and expanded in situ using a balloon catheter.

U.S. Patent 4,733,665 discloses an expandable intraluminal graft which is constituted by a tubular member formed from a plurality of intersecting elongate members which permit radial expansion and compression of the stent.

EP-A-0556850 discloses an intraluminal stent which is constituted by a sinuous wire formed into a helix; juxtaposed apices of the wire are secured to one another so that each hoop of the helix is supported by its neighboring hoops to increase the overall strength of the stent and to minimize the risk of plaque herniation; in some embodiments the stent of EP-A-0556850 further comprises a tubular graft member to form an endoluminal prosthesis.

The prior art stents and prostheses mentioned above are generally satisfactory for the treatment of aneurysms, stenoses and other angiological diseases at sites in continuous unbifurcated portions of arteries or veins.

However, the prior art stents and prostheses are not wholly satisfactory for use where the site of

desired application of the stent or prosthesis is juxtaposed or extends across a bifurcation in an artery or vein such, for example, as the bifurcation in the mammalian aortic artery into the common iliac arteries.

5 For example, in the case of an abdominal aortic aneurysm ("AAA") in the infrarenal portion of the aorta which extends into one of the common iliac arteries, the use of one of the prior art prosthesis referred to above across the bifurcation into the one iliac artery will result in

10 obstruction of the proximal end of the other common iliac artery; by-pass surgery is therefore required to connect the one iliac artery in juxtaposition with the distal end of the prosthesis to the other blocked iliac artery. It will be appreciated by a person skilled in the art that

15 it is desirable to avoid surgery wherever possible; the requirement for by-pass surgery associated with the use of the prior art prosthesis in juxtaposition with a bifurcation in an artery therefore constitutes a significant disadvantage.

20 SUMMARY OF THE INVENTION

Throughout this specification, the term "proximal" shall mean "nearest to the heart," and the term "distal" shall mean "furthest from the heart."

25 According to one aspect of the present invention there is provided a stent connecting means for connecting two intraluminal stents one to the other to define a continuous lumen through the two stents, the

stent connecting means including a first stent including a male engaging portion which can be compressed radially inwardly, and a second stent including a female cooperating portion. The male engaging portion may be entered into the female cooperating portion in a radially compressed state and thereafter caused or allowed to expand in the female cooperating portion; the arrangement being such that in service the interengagement of the male engaging portion and the female cooperating portion serves to resist longitudinal separation of the two stents one from the other.

Typically, the first stent may include a proximal male engaging portion; the second stent may include a distal female cooperation portion. The male engaging portion may be flared radially outwardly towards its extremity, and the female cooperating portion may be tapered radially inwardly towards its extremity. In some embodiments, the male engaging portion may comprise a frustoconical wall which flares outwardly towards its longitudinal extremity; the female engaging portion may comprise a frustoconical wall which tapers radially inwardly towards its longitudinal extremity.

Alternatively, said male engaging and female cooperating portions may be substantially untapered; they may be substantially cylindrical.

The male engaging portion of the first stent may be resiliently compressible in a radially inwards

direction such that in the radially compressed state it is capable of self-reexpansion to engage in the female cooperating portion. Typically, each of said first and second stents may be resiliently compressible.

5 In use therefore the second stent may be delivered in a radially compressed state by using a catheter; when the second stent is located at the site of use, the catheter may be withdrawn thereby allowing the second stent to re-expand to engage the endoluminal
10 surface of the blood vessel.

The first stent may then be delivered percutaneously or by a "cut down" technique to a site distal of the second stent such that the male engaging portion of the first stent in the radially compressed state is entered into the expanded female cooperating
15 portion of the second stent; the catheter may then be withdrawn allowing the first stent to re-expand such that the male engaging portion engages in the female cooperating portion of the second stent.

20 In some embodiments of the present invention the second stent may have two transversely spaced distal female cooperating portions; the second stent may therefore constitute a bifurcated stent for use in juxtaposition with a bifurcation in a blood vessel.

25 Each of the two transversely spaced distal female cooperating portions may be adapted for connection

to a first male stent which, in use, extends across the bifurcation into a respective one of the branched blood vessels.

5 In a particular aspect of the present invention there is provided a bifurcated intraluminal stent for use in juxtaposition with an angeological bifurcation; the bifurcated intraluminal stent comprising a proximal portion adapted to be positioned in service in a blood vessel in juxtaposition with a bifurcation, a first
10 distal stent portion adapted to extend across the bifurcation into one of the branched blood vessels and a second distal stent portion adapted to allow blood to flow from the proximal portion into the other branched vessel. The first distal stent portion may be formed
15 integrally with the proximal portion.

In some embodiments the second distal stent portion may comprise a female cooperating portion which is adapted to engage a male engaging portion of a another stent adapted to extend in the other branched blood
20 vessel such that, in use, the bifurcated stent can be connected in situ to the other stent. The bifurcated intraluminal stent may therefore constitute a second stent in accordance with the present invention comprising a distal female cooperating portion disposed intermediate
25 the proximal and distal extremities of the stent; the other stent may constitute a first stent in accordance with the present invention.

Typically, the proximal end of said second stent may be flared radially outwardly towards its extremity to engage the endoluminal surface of the artery thereby to resist longitudinal movement of the second stent in service.

Each of the first and second stents may comprise a sinuous wire formed into a tubular configuration. The sinuous and tubular configurations may be imparted to the wire by winding it on a mandrel. Typically, each stent may be made from a shape memory nitinol (nickel~titanium) wire which may be wound on to the mandrel to form the stent in a tubular configuration of slightly greater diameter than the diameter of the blood vessel in which the stent is intended to be used. The stent may be annealed at an elevated temperature and then allowed to cool in air so that the nitinol wire "remembers" the configuration in which it was wound on the mandrel.

Said nitinol wire may be type "M" nitinol wire which is martensitic at temperatures below about 13°C and is austenitic at temperatures above about 25°C; it will be appreciated therefore that the type "M" wire will be austenitic at body temperature of 37°C. Typically, the annealing may be conducted at about 500°C or more for at least about 60 minutes; after cooling the wire may be immersed in cold water to facilitate removal of the wire from the mandrel with the wire in its maleable martensitic form. Typically, the cold water may have

temperature of less than about 10°C; the wire may be immersed for about 5 minutes or more. An advantage of using nitinol wire to form the stent in accordance with the present invention is that the nitinol wire is "super elastic" in its austenitic state; the radial outward force exerted by the stent on the wall of the blood vessel in use is therefore substantially constant irrespective of the diameter of the vessel and the expanded stent.

In some embodiments the wire may have a helical configuration as disclosed in EP-A-0556850. Alternatively, the wire may be of an entirely novel configuration, namely one in which the wire forms a plurality of hoops such that the plane of the circumference of each hoop is substantially perpendicular to the longitudinal axis of the stent. Each hoop may comprise a substantially complete turn of the wire having a sinuous configuration; optionally, as each hoop is completed, the point of winding the wire may be displaced longitudinally with respect to the winding axis to form the next hoop. When the next hoop is complete, the point of winding is moved further longitudinally with respect to the winding axis to the form the next succeeding hoop and so on.

It will appreciated that an advantage of this novel arrangement is that the planes of the hoops are not skewed with respect to the longitudinal axis of the stent; the longitudinal ends of the stent are "square" to

said longitudinal axis, so that when the stent is caused or allowed to expand in situ there is substantially no twisting of the stent as it shortens in length. It will be appreciated that this represents a significant advantage, as in areas of stenosis or aneurysm it is desirable to minimize the movement of the stent within the blood vessel so as to reduce the potential trauma to the patient. A stent of this configuration may be used, apart from the bifurcated embodiment otherwise taught herein, in any application which in stents generally have heretofor been used.

Typically, the stents of this invention whether of the helical or perpendicular variety, also comprise a securing means for securing an apex of the sinuous wire in one hoop to a juxtaposed apex of a neighboring hoop so that each hoop is supported by its neighbors. The securing means may comprise a loop element of a suture material, for example, to tie the juxtaposed apices together; the loop element may also comprise a loop formed of a thermoplastics material such, for example, as polypropylene. Alternatively, the securing means may be a bead formed of a thermoplastic material around juxtaposed apices. Also alternatively, the securing means may be a loop, ring, or staple formed of wire such as nitinol.

The male engaging portion and female cooperating portion, of the first and second interengaging stents of this invention, may be formed

separately from the remainder of the respective non-engaging portions of these stents and then the engaging and non-engaging portions secured to one another by securing means.

5 In one embodiment of the present invention, the proximal and distal stent portions of the bifurcated stent in accordance with the present invention may be formed separately; the distal end of the proximal stent portion may be secured to the wider proximal end of a first intermediate frustoconical stent portion; the
10 narrower distal end of the first intermediate frustoconical stent portion may be secured to the proximal end of the distal stent portion. The female cooperating portion of the bifurcated stent may be
15 constituted by a second frustoconical stent portion which is secured to the distal end of the proximal stent portion in juxtaposition with the first frustoconical portion.

Alternatively the first and second
20 frustoconical portions may be omitted; the proximal and distal stent portions may be secured directly one to the other.

The female cooperating portion may be constituted by a generally cylindrical stent portion
25 secured to said proximal stent portion in transversely spaced relation to the distal portion.

Each of the first and second stents of the bifurcated form of the present invention may carry a tubular graft layer formed from a biocompatible fabric in juxtaposition with the stent; the combined stent and graft layer constituting an endoluminal prosthesis. Typically the graft layer may be disposed externally of the stent; it will be appreciated however that in some embodiments the graft layer may be disposed internally of the stent. In some embodiments the graft layer may be secured to the stent by loop elements such, for example, as loops of polypropylene. The biocompatible fabric may be a polyester fabric or a polytetrafluoroethylene fabric; typically said fabric may be woven or a warp knitted polyester fabric. In some embodiments the woven or a warp knitted fabric may be formed in a seam-free bifurcated configuration as a sleeve for a bifurcated stent.

In some embodiments the male engaging portion of the first stent and the female cooperating portion of the second stent may be left uncovered. Alternatively, the fabric graft layer may extend to the proximal extremity on the external surface of the male engaging portion, and may be folded over the distal extremity of the female engaging portion to form an inner sleeve; in use the external fabric of the male engaging portion may butt against the folded over portion of the fabric internally of the female cooperating portion to form a substantially blood tight seal.

The present invention in one aspect therefore includes a bifurcated endoluminal prosthesis comprising a bifurcated stent in accordance with the invention and a tubular graft layer.

5 The first stent having the male engaging portion may also have a tubular graft layer. If required the first prosthesis may be introduced in a radially compressed state such that the male engaging portion of the first prosthesis is engaged in the intermediate
10 female cooperating portion of the bifurcated prosthesis; the first prosthesis is then caused to be allowed to re-expand in situ such that the male engaging portion engages in the female cooperating portion to resist longitudinal separation of the two prosthesis in service.

15 The bifurcated prosthesis may be adapted for use in the infrarenal portion of a mammalian aorta in juxtaposition with the bifurcation of the common iliac arteries for the treatment of abdominal aortic aneurysms. In use the bifurcated endoluminal prosthesis may be
20 introduced into the infrarenal portion of the aorta using a catheter such that the first distal stent portion extends into one of the branched iliac arteries; the catheter may then be withdrawn allowing the prosthesis to re-expand in situ.

25 It will be appreciated by a person skilled in the art that the prostheses may be introduced to the site of use percutaneously or by "cut down" techniques.

Any of the stents according to this invention may be provided on its external surface with circumferentially spaced wire barbs or hooks adapted to engage in the endoluminal surface of the host artery to resist longitudinal movement or slippage of the stent in use. Typically the barbs or hooks may be disposed on part of the stent which is provided with a fabric graft layer such that in use the points of the artery which are engaged by the barbs or hooks are covered by the fabric graft. It will be appreciated by a person skilled in the art that the trauma to the artery wall caused by the hooks or barbs may cause emboli; the provision of the fabric graft over the barbs or hooks in use will therefore help to prevent the introduction of such emboli into the blood stream.

The male engaging portion for the first stent may be provided with circumferentially spaced hooks or barbs on its external surface to engage the internal surface of said female cooperating means, thereby to reinforce the connecting means against longitudinal separation of the stents one from the other in the service.

The present invention therefore provides a connecting means for connecting two stents longitudinally one to the other. It will be appreciated that this represents a significant step forward in the art as it allows the provision of a bifurcated endoluminal prosthesis for use in juxtaposition e.g. with arterial

bifurcations without requiring by-pass surgery to connect one of the branched arteries to the other branched artery.

5 In particular, the invention provides a
bifurcated endoluminal prosthesis which can be positioned
in an artery in juxtaposition with a bifurcation to
extend into one of the branched arteries; the bifurcated
prosthesis can be connected to another prosthesis which
10 extends into the other branched artery. The prosthesis
can be delivered percutaneously or by "cut down" methods
and connected together in situ thereby to provide
effective treatment of an angeological disease such, for
example, as an aneurysm or a stenosis which extends
15 across a bifurcation in a blood vessel without the need
for by-pass surgery.

20 In another aspect, this invention provides an
introducer for delivering, into the vasculature at an
angeological bifurcation where a blood vessel branches
into two branched vessels, a bifurcated endoluminal stent
or prosthesis having a proximal portion adapted to be
disposed in the blood vessel and a distal portion adapted
to be disposed at least partially in one of the two
branched vessels. The introducer comprises a tubular
25 outer sheath, a proximal portion pusher disposed at least
partially within the outer sheath, and a distal portion
pusher disposed at least partially within the proximal
portion pusher.

The present invention further provides an introducer for delivering into the vasculature at an angeological bifurcation where a blood vessel branches into two branched vessels, an endoluminal prosthesis having a proximal stent portion and a distal stent portion. The introducer comprises a tubular outer sheath, a proximal portion pusher disposed at least partially within the outer sheath and having a proximal end adapted to contact the proximal stent portion, a distal portion pusher disposed at least partially within the proximal portion pusher and having a proximal end adapted to contact the distal stent portion; and a balloon catheter, having a balloon attached thereto, disposed at least partially within the distal portion pusher.

This invention in another aspect provides a method for delivering a bifurcated endoluminal stent or prosthesis having a proximal portion and a first distal portion into the vasculature at an angeological bifurcation where a blood vessel branches into a first branched vessel and a second branched vessel. The method comprises inserting a first introducer containing the stent or prosthesis into the vasculature to a predetermined delivery location, the first introducer comprising an outer sheath, a proximal portion pusher, and a distal portion pusher; withdrawing the outer sheath of the first introducer while maintaining the proximal portion pusher in a fixed position until the proximal portion of the stent or prosthesis is deployed from the

first introducer into the blood vessel; withdrawing the outer sheath and the proximal portion pusher while maintaining the distal portion pusher in a fixed position until the first distal portion of the stent or prosthesis is deployed from the first introducer at least partially into the first branched vessel; and withdrawing the first introducer from the vasculature.

This invention further provides a method for delivering, into the vasculature at an aneological bifurcation where a blood vessel branches into two branched vessels, an endoluminal prosthesis having a proximal stent portion, and a distal stent portion. The method comprises the steps of inserting an introducer containing the prosthesis into the vasculature to a predetermined delivery location, the introducer comprising an outer sheath, a proximal stent portion pusher, a distal stent portion pusher, and a balloon catheter having a balloon attached thereto; inflating the balloon to at least partially block blood flow in the blood vessel; withdrawing the outer sheath of the introducer while maintaining the proximal stent portion pusher in a fixed position until the proximal stent portion of the prosthesis is deployed from the introducer into the blood vessel; withdrawing the outer sheath and the proximal stent portion pusher while maintaining the distal stent portion pusher in a fixed position until the distal stent portion of the prosthesis is deployed from the introducer into the blood vessel; and withdrawing the introducer from the vasculature.

In general, this invention provides a method of treating an angeological disease at a bifurcation site where a blood vessel branches into a first branched vessel and a second branched vessel comprising the steps
5 of disposing in the blood vessel a proximal portion of an endoluminal stent; directing blood flow from the blood vessel into the first branched vessel through a first distal portion of the endoluminal stent, the first distal portion being connected to the proximal portion and
10 extending into the first branched vessel; and directing blood flow from the blood vessel into the second branched vessel through a second distal portion of the endoluminal stent, the second distal portion being connected to the proximal portion and extending into the second branched
15 vessel. This method may be applied to aneurysms, occlusions, or stenosis.

Following is a description by way of example only and with reference to the accompanying drawings of the present invention, including novel stent
20 constructions and methods of manufacture and use thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

The aspects, features and advantages of the present invention will be more readily understood from the following detailed description when read in conjunction with the accompanying drawings, in which:

Figure 1a is a front view of a bifurcated intraluminal stent in accordance with the present invention constituting part of an endoluminal prosthesis.

Figure 1b is a front view of another stent which is adapted to be connected to the bifurcated stent of Figure 1a.

Figure 2(a) is a side view of part of the bifurcated stent of Figure 1a opened up to show its construction.

Figure 2(b) is a side view of an exemplary mandrel used to form the part of the bifurcated stent shown in Figure 2(a).

Figure 3 is a side view of another part of the bifurcated stent of Figure 1a opened up to show its construction.

Figure 4(a) is a side view of yet another part of the bifurcated stent of Figure 1a opened up to show its construction.

Figures 4(b)-4(f) are partial exploded views of the exemplary stent of Figure 4(a) illustrating alternative means for securing juxtaposed apices according to the present invention.

5 Figure 5 is a schematic perspective view of a bifurcated endoluminal prosthesis in accordance with the present invention.

10 Figure 6 is a schematic view of another bifurcated endoluminal prosthesis in accordance with the present invention.

Figure 7 is a schematic view of yet another bifurcated endoluminal prosthesis in accordance with the present invention.

15 Figure 8(a) is a cross-sectional view of an exemplary assembled introducer according to the present invention.

Figures 8(b)-8(e) are side views of the component parts of the introducer of Figure 8(a).

20 Figure 8(f) is a partial cross-sectional view of the introducer of Figure 8(a).

Figure 8(g) is a cross-sectional view of part of the introducer of Figure 8(f) taken along the line A-A.

Figure 9 is a side cross-sectional view of a portion an alternative embodiment of an introducer according to the present invention.

Figures 10(a) and 10(b) are side views of other alternative embodiments of an introducer according to the present invention.

Figures 11 through 20 are sequential cross-sectional views of the bifurcation of the abdominal aortic artery during introduction of an exemplary prosthesis according to the present invention.

Figures 21(a)-21(c) are cross-sectional views of alternative insertion apparatus according to the present invention.

Figures 22 and 23 are side views of alternative stents according to the present invention.

Figures 24(a), 24(b), 25, 26 and 27 are sequential cross-sectional views of the bifurcation of the abdominal aortic artery during introduction of an exemplary prosthesis according to the present invention.

Figures 28 and 29 are cross-sectional side views of alternative delivery apparatus according to the present invention.

Figures 30-34 are sequential cross-sectional views of the bifurcation of the abdominal aortic artery during introduction of an exemplary prosthesis according to the present invention.

DETAILED DESCRIPTION

The present invention includes apparatus and method for treating angeological diseases in any bifurcated blood vessel. One example of such a bifurcated blood vessel is the infrarenal portion of a mammalian aortic artery where it bifurcates to the common iliac arteries. Examples of diseases that can be treated using the apparatus and method of the present invention include aneurysm, stenosis, and occlusion.

A bifurcated stent in accordance with the present invention which is indicated at 10 in Figure 1a comprises a wire skeleton which is constructed in four separate parts, namely a proximal part 12, a first frustoconical part 14, a first distal part 16 and a second frustoconical part 18. Said bifurcated stent 10 carries a fabric graft layer (Figures 5, 6, and 7) for use as an endoluminal prosthesis e.g. in the infrarenal portion of a mammalian aorta in juxtaposition with the

bifurcation of the common iliac arteries. It will be appreciated, however, that bifurcated stents (with or without fabric graft layers) for use in different parts of the angeological system and for different mammals can be constructed in accordance with the invention by
5 varying the dimensions of the stent accordingly.

Each of the four parts of the bifurcated stent 10 is made in substantially the same way by winding a shape memory nitinol wire, typically nitinol type M wire, onto a mandrel 46.

The construction of the exemplary proximal part 12 of the bifurcated stent 10 is shown in Figures 2(a) and 2(b); nitinol wire type M wire typically having a diameter of 0.46mm (0.018") is wound around mandrel 46 to
15 form a plurality of hoops 20. The winding surface of mandrel 46 is provided with a plurality of upstanding pins 47 disposed in a zig-zag pattern for each of the hoops 20 so that in each hoop 20 the nitinol wire follows a sinuous path to define a plurality of circumferentially spaced apices 22. Each hoop 20 is wound onto mandrel 46
20 such that the plane of the circumference of each hoop 20 is substantially perpendicular to the longitudinal axis of the mandrel.

When one hoop 20 e.g. the hoop indicated at 20a has been formed, the point of winding of the nitinol wire is displaced longitudinally with respect to the axis of
25 mandrel 46 to form the next successive hoop 20b. The

stent shown in Figure 2(a) is the stent formed on mandrel 46 shown in Figure 2(b) after cutting the stent longitudinally and rotating it 45 degrees to show the construction of the stent.

5 The proximal part of the exemplary bifurcated stent of Figure 1a is formed on the mandrel with a diameter of about 24mm and a length in the longitudinal direction of about 55mm. From Figures 1(a), 2(a), and 2(b) it will be noted that the proximal part 12 is
10 constituted by three hoops 20 of unit width at the proximal end 24 of the proximal part 12, two intermediate hoops 25 of twice unit width and, at its distal end 26, by a single hoop 20 of unit width. In the illustrated embodiment, intermediate hoops 25 have a plurality of
15 offsets 25a. Offsets 25a are formed when the wire is passed around pins 47 on mandrel 46. Offsets 25a add stability to the stent. When the nitinol wire has been wound onto mandrel 46, the nitinol wire is annealed at an elevated temperature and then allowed to cool.

20 In this embodiment of the invention the wire is annealed at a temperature of about 500°C for 60 minutes and is then allowed to cool in air. The purpose of the annealing is so that the nitinol wire in its austenitic form "remembers" its configuration as wound on mandrel
25 46; it will be appreciated therefore that other temperatures and durations for the annealing are included within the present invention provided the nitinol wire "remembers" its wound configuration.

After annealing and cooling, the wire is immersed in cold water at less than 10°C for about 5 minutes; the wire is then removed from the mandrel, and juxtaposed apices 22 of neighboring hoops 20 are secured together by securing means 99 (see Figure 4(a)), which are, in this example, 0.003" polypropylene filaments. Each apex 22 of each hoop 20 which has a juxtaposed apex of a neighboring hoop 20 is tied to the juxtaposed apex 22. It will be appreciated, however, that in other embodiments of the invention only some of the juxtaposed apices 22 may be secured in this way.

In addition to polypropylene filaments, the securing means may comprise a loop element 99a of a suture material, for example, to tie the juxtaposed apices together, as shown in Figure 4(b). The securing means may also comprise bead 99b formed of a thermoplastic material around juxtaposed apices, as shown in Figure 4(c). Also alternatively, the securing means may be a loop 99c, ring 99d, or staple 99e formed of wire such as nitinol, as shown in Figures 4(d), 4(e), and 4(f) respectively.

The exemplary first and second frustoconical parts 14, 18 of the skeleton shown in the figures are formed in substantially the same way as the proximal part 12 by winding nitinol wire onto a mandrel and then annealing the wire before removing it from the mandrel. As shown in Figure 3, the first and second frustoconical parts 14, 18 are each constituted by three hoops 20 of

unit width. The mandrel is tapered such that the proximal end of each of the exemplary frustoconical parts 14, 18 is formed with a diameter of about 12mm and the distal end 32 of each is formed with a diameter of about 9mm. The overall length of each of the exemplary frustoconical parts 14, 18 is about 18mm. The wire used for the frustoconical parts 14, 18 is nitinol type M wire having a diameter of 0.28mm (0.011"). Juxtaposed apices 22 of each of the exemplary frustoconical parts 14, 18 are tied together using 0.03" polypropylene filaments as described above. The first and second frustoconical parts 14, 18 are secured to the distal end 26 of the proximal part 12 of the stent 10 in transversely spaced relation as shown in Figure 1a by securing the apices 22 of the hoop 20 forming the wider proximal end 30 of each of the frustoconical parts 14, 18 to juxtaposed apices 22 of the hoop 20 on the distal end 26 of the proximal part 12.

The exemplary first distal part 16 of the bifurcated stent 10 is formed by winding nitinol type M wire typically having a diameter of 0.28mm (0.011") onto a mandrel to form twelve longitudinally spaced hoops 20 as shown in Figure 4; the exemplary first distal part has an overall length of about 66mm and a uniform diameter of about 9mm. The proximal end 34 of the distal part 16 is secured to the narrower distal end 32 of the first frustoconical part 14 by tying each apex 22 on the proximal end 34 of the first distal part 16 to a juxtaposed apex on the distal end 32 of the first

frustoconical part 14 using, in this embodiment, 0.003" polypropylene filaments.

5 The proximal part 12, the first and second frustoconical parts 14, 18, and the first distal part 16 are each covered with a tubular graft layer of a biocompatible woven fabric (Figures 5, 6, and 7) such, for example, as a plain woven fabric made from 30 or 40 denier polyester. The tubular fabric layers may be attached to the proximal and distal parts 12, 16 of the stent 10 by stitching with, for example, 0.003" polypropylene filaments around the apices 22 of the underlying skeleton. The fabric covered stent constitutes one form of an endoluminal prosthesis.

15 The proximal part 12 of the wire skeleton may be provided with a plurality of circumferentially spaced hooks or barbs 43 which project through the tubular fabric layer to engage in the endoluminal surface of a host artery in service.

20 The sinuous configuration of each turn 20 of the wire skeleton of the stent 10 allows the prosthesis to be compressed resiliently radially inwards so that it can be received in a catheter e.g. a 16 or 18 French catheter for percutaneous or cut down delivery, e.g. to an intraluminal site in the infrarenal section of the aortic artery. Larger diameter catheters up to, e.g., 20 French, may be used to deliver the prosthesis using "cut down" procedures.

An x-ray opaque marker may be attached to one or more ends of a stent so that the delivery of the stent can be monitored using x-rays. As shown in Figure 4(a), such a radiopaque marker may typically comprise a gold or platinum wire 17 crimped onto an end of stent 16.

Alternatively, the radiopaque marker may be a tube 17a disposed around a length of wire on the stent, also as shown in Figure 4(a). Typically, in the bifurcated stent the marker is secured to the stent in line with the distal stent portion so that the distal stent portion can be aligned with and inserted into one of the branched arteries in situ.

The bifurcated endoprosthesis is positioned in the infrarenal section of the aortic artery in juxtaposition with the bifurcation of the common iliac arteries such that the first distal part 16 of the prosthesis extends into one of the common iliac arteries. The catheter is then withdrawn allowing the stent 10 to re-expand towards its configuration as wound on the mandrel in which it was annealed until the stent engages the endoluminal surface of the host artery. The barbs or hooks engage the endoluminal surface of the host artery to resist longitudinal displacement or slipping of the prosthesis in use.

It will be appreciated that when the bifurcated prosthesis is positioned and re-expanded in the fitted position, blood can flow from the aortic artery into the proximal part 12 of the prosthesis from where it can flow

into the one common iliac artery through the frustoconical part 14 and the first distal part 16 and also into the other common iliac artery through the second frustoconical part 18.

5 In cases where it is required to implant a prosthesis in the other common iliac artery a second prosthesis comprising a second stent 40 as shown in Figure 1b can be used. The second stent 40 includes a wire skeleton comprising a proximal frustoconical part 42 and a distal part 44. The distal part 44 of the second
10 stent 40 also may be covered with a tubular graft layer of a biocompatible fabric such, for example, as polyester or polytetrafluoroethylene fabric (Figures 5, 6, and 7).

The frustoconical proximal part 42 is
15 constructed in the same way as the frustoconical parts 14, 18 of the bifurcated stent 10; the distal part 44 is constructed in the same way as the distal part 16 of the bifurcated stent 10. The distal end of the frustoconical proximal part 42 is secured to the proximal end of the
20 distal part 44 by securing juxtaposed apices using polypropylene filaments as described above.

In use, the second prosthesis is compressed radially inwards and is received in a catheter for percutaneous or "cut down" delivery to the other common
25 iliac artery. The frustoconical proximal part 42 is guided, in the radially compressed state, into the second frustoconical part 18 of the bifurcated stent 10. The

catheter is then withdrawn allowing the second stent 40 to re-expand towards its remembered configuration, until the distal part 14 engages the endoluminal surface of the other common iliac artery, and the outer surface of the frustoconical proximal part 42 engages the interior surface of the second frustoconical part 18 of the bifurcated stent 10.

As with other stents described herein, the frustoconical proximal part 42 may be formed with circumferentially spaced barbs or hooks 43, as shown in Figure 1b, which engage in the wire skeleton of the second frustoconical part 18 of the bifurcated stent 10. When barbs 43 are on proximal portion 12, they engage the inner wall of the artery.

The tapered configurations of the second frustoconical part 18 of the bifurcated stent 10 and of the proximal frustoconical part 42 of the second stent 40 are such that in the fitted position as described, the prosthesis are locked together to resist longitudinal separation in service. Barbs or hooks on the second stent 40 and/or an frustoconical proximal part 42 help to resist such longitudinal separation.

In another example of the present invention a bifurcated endoluminal prosthesis 50 as shown in Figure 5 includes a bifurcated stent comprising a proximal portion 52 which tapers radially inwardly from its proximal end 54 to its distal end 56, and first and second

transversely spaced frustoconical distal portions 58, 60 which are secured to the distal end 56 of the proximal portion 52; the proximal portion 52 is covered with a tubular graft layer of a biocompatible fabric 62.

5 In use the prosthesis is delivered percutaneously or by "cut down" methods to an artery in juxtaposition with an arterial bifurcation; blood can flow through the frustoconical proximal portion 52 into each of the branched arteries through the first and
10 second distal frustoconical portions 58, 60. If a prosthesis is required in one or both of the branched arteries, a separate prosthesis comprising a stent of the type shown in Figure 1b referred to above covered with fabric can be connected to the bifurcated prosthesis 50
15 by inserting and re-expanding the proximal end of such a separate prosthesis in one or both of the distal frustoconical portions 58, 60 of the prosthesis 50 for engagement therein.

20 Another variant of the present invention is shown in Figure 6 which shows a bifurcated endoluminal prosthesis 70 having a proximal portion 72 which is secured at its distal end 74 to two transversely spaced frustoconical intermediate portions 76, 78.

25 One of said frustoconical intermediate portions 76 is secured at its distal end to an elongate distal portion 80. The proximal end 82 of the proximal portion 72 is flared radially outwards towards its proximal end

82 to engage the intraluminal surface of the host blood vessel in service. Save for this flared portion, the entire endoprosthesis is covered with a fabric graft layer as shown in Figure 6; said graft layer is carried externally of the wire skeleton and is folded over the distal extremity 84 of the other frustoconical intermediate portion 78 to form an internal lining in said other frustoconical immediate portion 78.

Said other frustoconical intermediate portion 78 constitutes a female cooperating portion in accordance with the present invention which is adapted to receive a male engaging portion of another prosthesis as indicated at 86 in Figure 6. Said other prosthesis 86 includes a frustoconical proximal portion 88 which constitutes the male engaging portion and an elongate distal portion 90. The whole of the other prosthesis 86 is covered with a fabric graft layer as shown in Figure 6. In service, the male engaging portion 88 of the other prosthesis 86 is entered into and engaged with the female cooperating portion 78 of the bifurcated prosthesis 70 in situ in the manner herein before described. The fabric layer on the male engaging portion 88 butts face-to-face on the folded over portion of the fabric layer disposed internally of the female cooperating portion 78 to form a substantially blood-tight seal therewith.

Yet another example of the present invention is shown in Figure 7 in which a bifurcated endoluminal prosthesis 91 has a generally cylindrical proximal

portion 92; said proximal portion 92 is connected at its distal end 93 to an elongate, generally cylindrical distal portion 94. Said proximal portion 92 is also connected at its distal end 93 to a generally cylindrical intermediate portion 95 which is secured in transversely spaced relation to the elongate distal portion 94. Said cylindrical intermediate portion 95 constitutes a female engaging portion which is adapted to receive a generally cylindrical male engaging portion of a second elongate prosthesis (not shown). The male engaging portion is equipped with circumferentially spaced external barbs to engage in the female cooperating portion in service. As shown in Figure 7, the whole of the bifurcated prosthesis 91 is covered with an external fabric graft layer save for a flared portion 96 towards the proximal end 97 of the proximal portion 92.

Referring to Figures 8(a)-8(f), an exemplary embodiment of a delivery system according to the present invention will be described. This system is used to deploy the bifurcated stent 10 when it is covered with a fabric graft layer to create an endoluminal prosthesis. Introducer 100 includes outer sheath 101. Outer sheath 101 is a cylindrical tube adapted to be inserted either percutaneously or by "cut-down" procedures into the vasculature from an entry point to the bifurcation site where the prosthesis is to be deployed.

Housed within outer sheath 101 is proximal portion pusher 102. Proximal portion pusher 102 is a

cylindrical tube having an outside diameter smaller than the inside diameter of outer sheath 101. Proximal portion pusher 102 is preferably slidable throughout the length of outer sheath 101.

5 Disposed within proximal portion pusher 102 is distal portion pusher 103. Distal portion pusher 103 is a cylindrical tube slidably contained within distal portion pusher 102. Distal portion pusher 103 is preferably adapted to slide throughout the entire length of proximal portion pusher 102.

10 Disposed within distal portion 103 is balloon catheter 104. Balloon catheter 104 is adapted to slide within distal portion pusher 103. At the leading end 105 of balloon catheter 104 is nose cone 106. Balloon 107 is attached to balloon catheter 104 between nose cone 106 and proximal end 115 of proximal portion pusher 102.

15 As shown in Figure 8(g), which is a cross-sectional view of balloon catheter 104 in the direction A-A of Figure 8(f), balloon catheter 104 has a guide wire conduit 104a. Guide wire conduit 104a extends throughout the length of balloon catheter 104 for passing a guide wire (not shown) through introducer 100. In the illustrated embodiment, balloon catheter 104 also includes injection orifice 109 and an injection conduit 109a. Injection conduit 109a connects injection orifice 109 to an injection site 108 at or near the distal end of balloon catheter 104 as shown in Fig. 8(e). Radiopaque

liquid may be injected into injection site 108, through injection conduit 109a, out injection orifice 109, and into the vasculature to monitor deployment of the prosthesis.

5 Also in the illustrated embodiment of Figures 8(f) and 8(g), balloon catheter 104 has an inflation orifice 110 located at a point where balloon 107 is attached to balloon catheter 104. A balloon inflation conduit 110a connects balloon inflation orifice 110 to
10 balloon inflation site 111 (Figure 8(e)). Balloon 107 may be inflated and deflated from balloon inflation site 111 during delivery of the prosthesis.

15 In an alternative embodiment illustrated in Fig. 9, seals 150, 151 may be disposed around the distal ends 160, 161 of outer sheath 10 and proximal portion pusher 102. Seals 150, 151 may be formed of silicone tubes.

20 Fig. 10(a) shows an alternative embodiment of introducer 100. As shown in Fig. 10(a), wings 112 and 113 are provided at the distal end of introducer 100. Wing 112 is connected to proximal portion pusher 102, and wing 113 is connected to outer sheath 101. Wings 112 and 113 indicate the rotational orientation of proximal
25 portion pusher 102 and outer sheath 101, respectively. This in turn indicates the orientation of proximal portion 12 within outer sheath 101 and distal portion 16 within proximal portion pusher 102. Wings 112 and 113 in

the illustrated embodiment are also provided with holes 112a and 113a.

As shown in Figure 10(b), a rod 128 or other fixation device may be attached to wings 112 and 113 using e.g. bolts through holes 112a and 113a secured by wing nuts 129 or other securing means. Rod 128 prevents relative movement of proximal portion pusher 102 and outer sheath 101. Wings may also be provided on distal portion pusher 103 and used to secure distal portion pusher 103 to either proximal portion pusher 102 or outer sheath 101 using a fixation device as described above.

Also shown in Fig. 10(a) as part of introducer 100 is hemostasis valve 114. Hemostasis valve 114 is connected to distal portion pusher 103 and acts as a simple seal around balloon catheter 104. Although it prevents fluid loss, hemostasis valve 114 allows balloon catheter 104 to slide within distal portion pusher 103. Alternatively, a Touhy-Borst valve (not shown) may be used instead of hemostasis valve 114. The Touhy-Borst valve is a device that may be manually tightened over balloon catheter 104. Lightly tightening such a valve permits balloon catheter 104 to slide; firmly tightening such a valve clamps balloon catheter 104 in place.

In use, the prosthesis must first be loaded into introducer 100. Outer sheath 101 is first removed from introducer 100. Balloon catheter 104 is then threaded through distal portion 16 and proximal portion

12 of the prosthesis. The prosthesis is then cooled to a temperature of approximately 10°C or below and radially compressed. For this purpose, the prosthesis may be immersed in cold water. The prosthesis should
5 preferably remain in the water during the loading operation.

As supporting stent 10 is compressed beneath the fabric covering of the prosthesis, excess fabric is produced. This excess fabric may simply be pinched
10 together and laid over the compressed prosthesis in longitudinal folds.

Distal portion 16 of the prosthesis in the radially compressed state is then inserted into proximal portion pusher 102. Outer sheath 101 is then pulled over
15 proximal portion 12 of the prosthesis and over proximal portion pusher 102. A thread (not shown) may be attached to the proximal end of proximal portion 12 of the prosthesis and threaded through outer sheath 101. This thread may then be used to pull proximal portion 12
20 through outer sheath 101. During the loading process, it is important to keep proximal portion 12 and distal portion 16 of the prosthesis properly aligned with outer sheath 101 and proximal portion pusher 102. Marks may be placed on the outside of outer sheath 101 and proximal
25 portion pusher 102 to ensure proper alignment.

Referring again to Fig. 8(f), the prosthesis is inserted such that the outer surface of proximal portion

12 contacts and is radially restrained by outer sheath 101, and the outer surface of distal portion 16 contacts and is radially restrained by proximal portion pusher 102. End 115 of proximal portion pusher 102
5 longitudinally engages proximal portion 12 of the prosthesis as shown in Fig. 8(f).

Balloon catheter 104 is positioned such that nose cone 106 just clears proximal end 117 of outer sheath 101. The introducer is now in condition for insertion into the patient.

Referring to Fig. 11, introducer 100 is passed through an entry point (not shown) either in the patient's skin (percutaneous operation) or into the vasculature itself which has been surgically exposed ("cut-down" operation). Introducer 100 is inserted over a guide wire 170 into the vasculature from the entry point to the desired delivery location at an aneological bifurcation.

In the aorta, introducer 100 is positioned such
20 that end 117 of outer sheath 101 is approximately level with renal arteries 180 as shown in Figure 11. Balloon catheter 104 is then extended while maintaining outer sheath 101 in a fixed position. Balloon catheter 104 in this embodiment is extended until distal end 105 of nose
25 cone 106 is approximately 35 mm above the proximal tip 117 of outer sheath 101. Then, while maintaining proximal portion pusher 102 in a fixed position, outer

sheath 101 is withdrawn until the proximal tip of the prosthesis is level with proximal tip 117 of outer sheath 101. It will be noted that balloon catheter 104 does not move while outer sheath 101 is so withdrawn.

5 Introducer 100 is then repositioned to place the prosthesis in the desired deployment location. Proper placement may be facilitated with the use of radiopaque markers as described above. Balloon catheter 104 is then extended such that balloon 107 is above renal arteries 180. Balloon 107 is then inflated to occlude the aorta as shown in Fig. 12.

10 While maintaining proximal portion pusher 102 in a fixed position, outer sheath 101 is withdrawn until the proximal end of the prosthesis emerges from outer sheath 101 as shown in Fig. 13. Using a radiopaque marker 120 disposed on proximal end of the prosthesis, the introducer is rotated until proper alignment of the prosthesis is obtained. In the illustrated embodiment, radiopaque marker 120 is a platinum wire twisted around
15 an apex of the prosthesis in a "V" shape. To ensure proper alignment, the stent should be rotated until only the profile of the V is seen and shows up as a straight line rather than a "V".

20 Outer sheath 101 is further withdrawn while
25 maintaining proximal portion pusher 102 fixed until proximal portion 12 is fully deployed from the end of

outer sheath 101, and the frustoconical portion 18 of the prosthesis just clears end 117, as shown in Figure 14.

Balloon 107 is then deflated to allow blood to flow through proximal portion 12 and out frustoconical portion 18 of the prosthesis. Balloon 107 is withdrawn into the prosthesis until the distal end 118 of nose cone 106 is just above the proximal end of the prosthesis. Balloon 107 is then inflated to seat the prosthesis, which may be provided with barbs (not shown) at its proximal end, against the wall of the aorta, as shown in Fig. 15.

Distal portion pusher 103 is then maintained in a fixed position while outer sheath 101 is withdrawn. Once outer sheath 101 has been withdrawn to the point at which proximal end 117 of outer sheath 101 is flush with proximal end 115 of proximal portion pusher 102, both outer sheath 101 and proximal portion pusher 102 are withdrawn, still maintaining distal portion pusher 103 in a fixed position. Outer sheath 101 and proximal portion pusher 102 are withdrawn until distal portion 16 of the prosthesis is deployed clear of proximal end 116 of distal portion pusher 103 as shown in Fig. 16. Balloon 107 is slowly deflated to allow blood flow to be established through the proximal portion 12 of the prosthesis and out through frustoconical portion 18. Balloon 107 may be used to model distal portion 16 of the prosthesis as necessary by inflating balloon 107 where needed to expand distal portion 16. Balloon 107 is then

deflated, and introducer 100 is withdrawn from the vasculature, leaving the guide wire 170 in place, as shown in Figure 17.

Figure 21(a) illustrates an exemplary second introducer 300 used for deploying second distal part 44. Second introducer 300 of the illustrated embodiment comprises cylindrical outer sheath 301 and female Luer lock assembly 310. Second introducer 300 also has hemostasis valve 361 contained within a hub 362 thereof. Cartridge 311 shown in Fig. 21(b) is adapted to be attached to second introducer 300. Cartridge 311 has threaded male Luer lock assembly 312 provided on its proximal end. Cartridge 311 has outer tube 313 which houses inner tube 314.

In use, a thin-walled tube (not shown) is first threaded through distal portion 44. This tube serves as a guide wire guide, allowing a guide wire to be threaded straight through distal portion 44 as discussed below. Distal portion 44 containing the thin-walled tube is then cooled, radially compressed, and inserted into inner tube 314 of cartridge 311 in a manner similar to that described for inserting the bifurcated prosthesis into proximal portion pusher 102 and outer sheath 101. When distal portion 44 has been loaded into inner tube 314 of cartridge 311, the thin-walled tube serving as a guide wire guide extends out both ends of cartridge 311.

A guide wire 171 is then inserted into the vasculature to the bifurcation site and through distal stent portion 12 as shown in Fig. 18. A dilator 359 (Figure 21(c)) having an outer diameter slightly less than the inner diameter of second introducer 300 is then inserted into second introducer 300 such that tapered end 360 extends out end 320 of second introducer 300. End 360 of dilator 359 has a hole therein that is just slightly larger than guide wire 171 and tapers gradually outward from the hole to the outer diameter of dilator 359.

Second introducer 300 is then inserted into the vasculature over guide wire 171 by passing guide wire 171 into and through dilator 359. Dilator 359 with tapered end 360 provides a smooth transition within the blood vessel from the diameter of guide wire 171 to the diameter of second introducer 300. Second introducer 300 is maneuvered such that outer sheath 301 is inside frustoconical portion 18 of proximal portion 12 by at least 20 mm in this embodiment, as shown in Fig. 19. Dilator 359 is then removed from second introducer 300 and from the vasculature and is discarded.

Cartridge 311 is then passed over guide wire 171 by passing guide wire 171 through the thin-walled guide wire guide within distal portion 44 contained in cartridge 311. The guide wire guide is then removed and discarded.

Cartridge 311 is then lockingly engaged with introducer 300 by mating male Luer lock assembly 310 with female Luer lock assembly 312. Such locking engagement prevents relative movement of cartridge 311 and
5 introducer 300. Preventing relative movement lends stability and reliability to the insertion process that has not heretofore been achieved.

A pusher 315 is then inserted into inner tube 314 of cartridge 311 such that proximal end 317 of pusher 315 longitudinally contacts a distal end of distal
10 portion 44 within inner tube 314. Pusher 315 pushes distal portion 44 through cartridge 311 and into outer sheath 301 of introducer 300. Distal portion 44 is pushed through outer sheath 301, which remains in a fixed
15 position, until distal portion 44 is at proximal end 320 of outer sheath 301 (see Figure 19). Again, radiopaque markers 120 may be used to align distal portion 44 properly with proximal portion 12.

Pusher 302 is held firmly in place, and outer
20 sheath 301 is withdrawn approximately 2 cm. This deploys frustoconical part 42 of distal part 44 inside the frustoconical part 18 as shown in Figure 19. The outer surface of frustoconical part 42 engages the inner surface of frustoconical part 18 such that distal portion
25 44 is connected to proximal portion 12 to resist longitudinal separation.

Outer sheath 301 may then be withdrawn while maintaining pusher 302 in a fixed position to fully deploy distal portion 44, as shown in Figure 20. If necessary, balloon catheter 104 may be inserted through sheath 301 in order to model distal portion 44. Introducer 301 and guide wires 170, 171 are then removed from the vasculature and the entry points are closed.

The delivery apparatus and method described above are particularly useful in treating an abdominal aortic aneurysm with a bifurcated prosthesis according to the present invention. Other diseases and alternative embodiments of the prosthesis and delivery method will now be described.

In the case of an abdominal aortic aneurysm confined to the aorta and not extending far enough to affect the iliac arteries, a straight (i.e. non-bifurcated) stent may be used. Preferably, for such applications, the straight stent comprises a composite of at least two axially aligned stent segments. Two embodiments of such straight stents are described therein, each comprising axially aligned stent requests, each of the requests comprising one or more adjacent hoops, perpendicular to a common axis, and each hoop being formed of wire in a sinuous or zigzag configuration with some or all of the juxtaposed apices in adjacent hoops secured to one another.

First, referring to Figure 22, straight stent 400 comprises proximal stent portion (or segment) 401, distal stent portion 402, and an intermediate portion 403.

5 Proximal portion 401 is a ring formed of a number of longitudinally spaced hoops 20 as described in connection with the formation of stent 10 above. In the illustrated embodiment, two hoops 20 are used, each hoop 20 having a unit width.

10 Distal portion 402 is also a ring formed of longitudinally displaced hoops 20 in the manner described above. Distal ring 402 has two hoops 20 of unit width in the illustrated embodiment.

15 Intermediate portion 403 of straight stent 400 is formed of biocompatible woven fabric such as, for example, a plain woven fabric made from 30 to 40 denier polyester. In this embodiment, intermediate fabric section 403 does not cover a stent. Fabric portion 403 is attached at its proximal and distal ends to the
20 proximal and distal stent portions, respectively, by stitching, for example, with 0.003 inch polypropylene filaments around apices 22 of the stent portions. Other than such connections at its longitudinal ends, intermediate fabric section 403 is unsupported by any
25 stent.

The second embodiment of a straight stent that may be used according to this invention is illustrated in Fig. 23. Straight stent 450 includes stent portion 451, constructed of wire loops as described above with reference to stent portions 401 and 402. Stent portion 451 is partially covered by fabric 452. In this embodiment, fabric portion 451 covers and is supported by stent 451, whereas with stent 400, the fabric portion 403 is not supported by a stent.

To treat an abdominal aortic aneurysm that does not extend down over the walls of the iliac arteries, as shown in Figure 24(a), straight stent 400 (or 450) is disposed as illustrated in Figure 26. Proximal stent portion 401 engages the inner walls of the aorta above the aneurysm. Distal stent portion 402 engages the inner wall of the aorta below the aneurysm. Intermediate fabric portion 403 extends across the aneurysm, providing a strong, stable lumen for blood flow through the aorta.

Figure 28 illustrates the delivery apparatus used to implant straight stent 400 in the vasculature. This apparatus is very similar to that described above for the delivery system to be used with the bifurcated stent or prosthesis. Accordingly, like reference numerals refer to the same components.

In the introducer 410 shown in Figure 28, proximal portion pusher 102 engages proximal stent

portion 401. Distal portion pusher 103 engages distal stent portion 402.

5 In use, straight stent 400 is first charged into the introducer by cooling it to temperatures below 10°C, radially compressing it, and inserting it within outer sheath 101, as described above in connection with the bifurcated stent or prosthesis. The remainder of introducer 410 is also assembled as described in connection with introducer 100.

10 Introducer 410 is passed through an entry point (not shown) over guide wire 411 as shown in Figure 24(a). This insertion may be accomplished using percutaneous or cut-down techniques. Introducer 410 is then inserted to the desired delivery location.

15 In the aorta, introducer 410 is positioned and balloon 107 is inflated above the renal arteries in the same manner as described above in connection with the bifurcated stent and as illustrated in Fig. 24(a).

20 While maintaining proximal portion pusher 102 in a fixed position, outer sheath 101 is withdrawn until proximal portion 401 of stent 400 emerges from outer sheath 101 as shown in Fig. 24(b). Using a radiopaque marker 420 disposed on the proximal end of the proximal portion 401, stent 400 is optimally aligned within the
25 aorta. Outer sheath 101 is further withdrawn until proximal portion 401 emerges therefrom, as shown in

Figure 25. Outer sheath 101 is then further withdrawn until it is flush with proximal portion pusher 102. Then both outer sheath 101 and proximal portion pusher 102 are withdrawn while maintaining distal portion pusher 103 in a fixed position. Distal portion 402 is thus deployed from the end of outer sheath 101, as shown in Figure 26.

Balloon 107 is then deflated and withdrawn inside proximal portion 401 where balloon 107 is re-inflated to seat the stent 400, as shown in Figure 27. Balloon 107 is then withdrawn, along with the introducer 410 as described above, and the entry point is closed.

Fig. 29 illustrates the apparatus used to deploy straight stent 450, shown in Figure 23, of the present invention. This apparatus is very similar to that described above for the delivery system to be used with the bifurcated stent or prosthesis. Accordingly, like reference numerals refer to the same components.

Proximal portion pusher 102 in this embodiment is glued to distal portion pusher 103 such that ends 115 and 116 are flush. These flush ends are adapted to engage stent 450 within outer sheath 101.

In use, straight stent 450 is first charged into introducer 490 by cooling it to temperatures below 10°C, radially compressing it, and inserting it within outer sheath 101, as described above in connection with the bifurcated stent or prosthesis. The remainder of

introducer 490 is also assembled as described in connection with introducer 100.

Introducer 490 is passed through an entry point (not shown) over a guide wire 411 as shown in Figure 30. This insertion may be accomplished using percutaneous or cut-down techniques. Introducer 490 is then inserted to the desired delivery location.

In the aorta, introducer 490 is positioned and balloon 107 is inflated above the renal arteries in the same manner as described above in connection with the bifurcated stent and as illustrated in Fig. 31.

While maintaining attached proximal portion pusher 102 and distal portion pusher 103 in a fixed position, outer sheath 101 is withdrawn until proximal portion 451 of stent 450 emerges from outer sheath 101 as shown in Fig. 32. Using a radiopaque marker 420 disposed on the proximal end of the proximal portion 451, stent 450 is optimally aligned within the aorta. Outer sheath 101 is then completely withdrawn until stent 450 is deployed into the aorta as shown in Fig. 33.

Balloon 107 is then deflated and withdrawn inside proximal portion 451 where balloon 107 is re-inflated to seat the stent 450, as shown in Figure 34. Balloon 107 is then withdrawn, along with the introducer 490 as described above, and the entry point is closed.

The angeological disease of occlusion is the blockage of an artery resulting from a buildup or clot of soft thrombus. There are two types of occlusions that can occur at the aorta-iliac bifurcation. The first is infrarenal occlusion. In this case, the blockage extends in the aorta from just below the renal arteries into the iliac arteries. The second type is an occlusion that is limited to the immediate area of the bifurcation.

To treat an infrarenal occlusion, a canalization is first made through the thrombus by methods known in the art. A bifurcated endoluminal prosthesis according to the present invention is then implanted at the bifurcation site to provide an unobstructed lumen extending from the aorta into each of the iliac arteries. Blood can thus flow freely from the aorta to the iliac arteries.

The bifurcated endoluminal prosthesis according to the present invention that is used to treat an occlusion must be fabric covered. This is necessary to prevent embolization from the thrombus remaining on the wall of the recanalized artery.

An occlusion at the bifurcation is treated by recanalizing the artery as above. A bifurcated endoluminal prosthesis according to the present invention may be implanted at the bifurcation. Because the occlusion is limited to the immediate bifurcation site,

however, the proximal portion of the prosthesis may be shorter than that discussed above.

To implant the bifurcated endoluminal prosthesis to treat both types of occlusion, the delivery system comprising introducer 100 discussed above for delivering the bifurcated endoluminal prosthesis to treat an abdominal aortic aneurysm is used. The same delivery method discussed above for implanting the bifurcated endoluminal prosthesis to treat abdominal aortic aneurysms is used to implant the device to treat the occlusion.

Using the method and apparatus of this invention to treat occlusion provides an unobstructed lumen through which blood can flow from the aorta to the iliac arteries.

The angeological disease of stenosis is a narrowing of an artery caused by a buildup of hard calcified plaque. This is usually caused by a buildup of cholesterol. To treat such an angeological disease, angioplasty is performed on the plaque according to methods well known in the art. The bifurcated endoluminal stent according to the present invention is then implanted at the bifurcation site. This stent is the same as that described above for treatment of an abdominal aortic aneurysm. To treat the stenosis, however, it is not necessary to cover the stent with a fabric, thus creating a prosthesis. Because restenosis

is rare at the bifurcation site, there is no need to isolate the blood flowing in the lumen from the walls of the arteries.

5 The delivery system used to implant the
bifurcated endoluminal stent used to treat stenosis is
the same as that illustrated in Figure 8 except that
balloon 107 is not required. Because there is no fabric
around the stent to be affected by blood flow in the
arteries and cause migration of the bifurcated stent, it
10 is not necessary to block the blood flow with the
balloon. Otherwise, the delivery system for implanting
the bifurcated stent to treat stenosis is the same as
that for implanting the bifurcated prosthesis to treat
abdominal aortic aneurysm.

15 Similarly, with the exception of the steps
involving inflation of balloon 107 to block blood flow,
the method of delivering the bifurcated endoluminal stent
to treat stenosis is the same as that described above for
delivering the bifurcated endoluminal prosthesis to treat
20 abdominal aortic aneurysm.

What is Claimed:

1 1. An introducer for delivering, into the
2 vasculature at an aneological bifurcation where a blood
3 vessel branches into two branched vessels, a bifurcated
4 endoluminal stent or prosthesis having a proximal portion
5 adapted to be disposed in said blood vessel and a distal
6 portion adapted to be disposed at least partially in one
7 of said two branched vessels, said introducer comprising:

8 (a) a tubular outer sheath;

9 (b) a proximal portion pusher disposed at
10 least partially within said outer sheath; and

11 (c) a distal portion pusher disposed at least
12 partially within said proximal portion pusher.

13 2. An introducer for delivering a bifurcated
14 endoluminal stent or prosthesis as claimed in claim 1
15 further comprising a balloon catheter, having a balloon
16 attached thereto, disposed at least partially within said
17 distal portion pusher.

18 3. An introducer for delivering a bifurcated
19 endoluminal stent or prosthesis as claimed in claim 2
20 further comprising a hemostasis valve attached to the
21 distal end of said distal portion pusher.

1 4. An introducer for delivering a bifurcated
2 endoluminal stent or prosthesis as claimed in claim 2
3 further comprising wings on said outer sheath and said
4 proximal portion pusher.

1 5. An introducer for delivering a bifurcated
2 endoluminal stent or prosthesis as claimed in claim 2,
3 wherein said balloon catheter has an injection orifice
4 and an injection conduit therein.

1 6. An introducer for delivering a bifurcated
2 endoluminal stent or prosthesis as claimed in claim 2,
3 wherein said balloon catheter has an inflation orifice
4 and an inflation conduit therein.

1 7. An introducer for delivering a bifurcated
2 endoluminal stent or prosthesis as claimed in claim 2,
3 wherein said balloon catheter has a proximal end with a
4 nose cone attached thereto.

1 8. An introducer for delivering into the
2 vasculature at an angeological bifurcation where a blood
3 vessel branches into two branched vessels, an endoluminal
4 prosthesis having a proximal stent portion and a distal
5 stent portion, said introducer comprising:

6 (a) a tubular outer sheath;

7 (b) a proximal portion pusher disposed at
8 least partially within said outer sheath and having a

9 proximal end adapted to contact said proximal stent
10 portion;

11 (c) a distal portion pusher disposed at least
12 partially within said proximal portion pusher and having
13 a proximal end adapted to contact said distal stent
14 portion; and

15 (d) a balloon catheter, having a balloon
16 attached thereto, disposed at least partially within said
17 distal portion pusher.

1 9. An introducer for delivering an
2 endoluminal stent into the vasculature at an aneological
3 bifurcation where a blood vessel branches into two
4 branched vessels, said introducer comprising:

5 (a) a tubular outer sheath;

6 (b) a proximal portion pusher disposed at
7 least partially within said outer sheath and having a
8 proximal end adapted to contact a distal end of said
9 stent; and

10 (c) a distal portion pusher disposed at least
11 partially within said proximal portion pusher and secured
12 to said proximal portion pusher such that proximal ends
13 of said distal portion pusher and said proximal portion
14 pusher are flush with one another.

1 10. A method for delivering a bifurcated
2 endoluminal stent or prosthesis having a proximal portion
3 and a first distal portion into the vasculature at an
4 aneological bifurcation where a blood vessel branches
5 into a first branched vessel and a second branched
6 vessel, said method comprising the steps of:

7 (a) inserting a first introducer containing
8 said stent or prosthesis into the vasculature to a
9 predetermined delivery location, said first introducer
10 comprising an outer sheath, a proximal portion pusher,
11 and a distal portion pusher;

12 (b) withdrawing said outer sheath of said
13 first introducer while maintaining said proximal portion
14 pusher in a fixed position until said proximal portion of
15 said stent or prosthesis is deployed from said first
16 introducer into said blood vessel;

17 (c) withdrawing said outer sheath and said
18 proximal portion pusher while maintaining said distal
19 portion pusher in a fixed position until said first
20 distal portion of said stent or prosthesis is deployed
21 from said first introducer at least partially into said
22 first branched vessel; and

23 (d) withdrawing said first introducer from the
24 vasculature.

1 11. A method for delivering a bifurcated
2 endoluminal stent or prosthesis as claimed in claim 10
3 further comprising the steps of:

4 (a) inserting into the vasculature a second
5 introducer containing a second distal portion of said
6 stent or prosthesis and comprising an outer sheath and a
7 pusher;

8 (b) withdrawing said outer sheath of said
9 second introducer while maintaining said pusher of said
10 second introducer in a fixed position until said second
11 distal portion of said stent or prosthesis is deployed
12 from said second introducer such that a proximal end of
13 said second distal portion securely connects to said
14 proximal portion of said stent or prosthesis, and such
15 that a distal end of said second distal portion extends
16 at least partially into said second branched vessel; and

17 (c) withdrawing said second introducer from
18 the vasculature.

1 12. A method for delivering a bifurcated
2 endoluminal stent or prosthesis as claimed in claim 10
3 wherein said first introducer further comprises a balloon
4 catheter having a balloon attached thereto and said
5 method further comprises the step of inflating said
6 balloon to at least partially block blood flow in said
7 blood vessel after inserting said first introducer into
8 the vasculature.

1 13. A method for delivering, into the
2 vasculature at an angeological bifurcation where a blood
3 vessel branches into two branched vessels, an endoluminal
4 prosthesis having a proximal stent portion, and a distal
5 stent portion, said method comprising the steps of:

6 (a) inserting an introducer containing said
7 prosthesis into the vasculature to a predetermined
8 delivery location, said introducer comprising an outer
9 sheath, a proximal stent portion pusher, a distal stent
10 portion pusher, and a balloon catheter having a balloon
11 attached thereto;

12 (b) inflating said balloon to at least
13 partially block blood flow in said blood vessel;

14 (c) withdrawing said outer sheath of said
15 introducer while maintaining said proximal stent portion
16 pusher in a fixed position until said proximal stent
17 portion of said prosthesis is deployed from said
18 introducer into said blood vessel;

19 (d) withdrawing said outer sheath and said
20 proximal stent portion pusher while maintaining said
21 distal stent portion pusher in a fixed position until
22 said distal stent portion of said prosthesis is deployed
23 from said introducer into said blood vessel; and

24 (e) withdrawing said introducer from the
25 vasculature.

1 14. A method of treating an angeological
2 disease at a bifurcation site where a blood vessel
3 branches into a first branched vessel and a second
4 branched vessel comprising the steps of:

5 (a) disposing in said blood vessel a proximal
6 portion of an endoluminal stent;

7 (b) directing blood flow from said blood
8 vessel into said first branched vessel through a first
9 distal portion of said endoluminal stent, said first
10 distal portion being connected to said proximal portion
11 and extending into said first branched vessel; and

12 (c) directing blood flow from said blood
13 vessel into said second branched vessel through a second
14 distal portion of said endoluminal stent, said second
15 distal portion being connected to said proximal portion
16 and extending into said second branched vessel.

1 15. A method of treating an angeological
2 disease at a bifurcation site where a blood vessel
3 branches into a first branched vessel and a second
4 branched vessel as claimed in claim 14 wherein said
5 disease is stenosis.

1 16. A method of treating an angeological
2 disease at a bifurcation site where a blood vessel
3 branches into a first branched vessel and a second
4 branched vessel as claimed in claim 14 that further
5 comprises covering any of said proximal portion, said

6 first distal portion, and said second distal portion with
7 fabric.

1 17. A method of treating an angeological
2 disease at a bifurcation site where a blood vessel
3 branches into a first branched vessel and a second
4 branched vessel as claimed in claim 16 wherein said
5 disease is an aneurysm.

1 18. A method of treating an angeological
2 disease at a bifurcation site where a blood vessel
3 branches into a first branched vessel and a second
4 branched vessel as claimed in claim 16 wherein said
5 disease is an occlusion.

1 19. An endoluminal stent comprising a
2 plurality of hoops which are axially displaced in a
3 tubular configuration along a common axis, each of said
4 hoops

5 (a) being formed by a substantially complete
6 turn of a sinuous wire having apices, and

7 (b) having a circumference that lies in a plane
8 substantially perpendicular to the longitudinal axis of
9 said stent;

10 wherein apices of adjacent hoops are juxtaposed
11 to one another, and at least two juxtaposed apices are
12 connected by a securing means.

1 20. A stent as recited in claim 19 in
2 combination with one or more additional stent segments.

1 21. A stent as recited in claim 20 wherein at
2 least one of said additional stent segments comprises a
3 plurality of hoops which are axially displaced in a
4 tubular configuration along a common axis, each of said
5 hoops

6 (a) being formed by a substantially complete
7 turn of a sinuous wire having apices, and

8 (b) having a circumference that lies in a plane
9 substantially perpendicular to the longitudinal axis of
10 said stent;

11 wherein apices of adjacent hoops are juxtaposed
12 to one another, and at least two juxtaposed apices are
13 connected by a securing means.

1 22. A stent as recited in claim 20 wherein
2 said one or more additional segments are axially aligned
3 with one another.

1 23. A stent as recited in claim 20 wherein
2 said one or more additional segments are secured to one
3 another by connecting means connecting at least some of

4 the apices of hoops at mating ends of said stent and said
5 additional segments.

1 24. A stent as recited in claim 20 wherein
2 adjacent hoops are of the same diameter.

1 25. A stent as recited in claim 20 wherein
2 adjacent hoops are of a different diameter.

1 26. A stent as recited in claim 22 wherein
2 said axially aligned segments are connected to one
3 another by a tubular fabric element.

1 27. A stent as recited in claim 20 wherein a
2 first additional segment is axially parallel to, but non-
3 common co-axial with, said stent.

1 28. A stent as recited in claim 27 further
2 comprising a second additional segment axially parallel
3 to said stent, but non-co-axial with either said stent or
4 said first additional stent segment.

1 29. A stent as recited in claim 28 wherein at
2 least one of said additional stent segments is of
3 frustoconical shape and is further combined with an
4 additional stent segment, one end of which includes a
5 mating frustoconical shape.

1 30. At stent as recited in claim 29, wherein
2 said mating frustoconical stent segments are adapted to
3 be separately placed in a bifurcated artery and then, by
4 expansion of one of said frustoconical stent segments,
5 secured to one another

1 31. An endoluminal stent as claimed in claim
2 19 wherein said hoops are formed of a single continuous
3 wire.

1 32. An endoluminal stent as claimed in claim
2 19 wherein said securing means is a suture.

1 33. An endoluminal stent as claimed in claim
2 32 wherein said suture is a tied loop of thermoplastic
3 material.

1 34. An endoluminal stent as claimed in claim
2 19 wherein said securing means is a ring.

1 35. An endoluminal stent as claimed in claim
2 19 wherein said securing means is a staple.

1 36. An endoluminal stent as claimed in claim
2 19 wherein said securing means is wire twisted into loop.

1 37. An endoluminal stent as claimed in claim
2 36 wherein said wire is nitinol.

1 38. An endoluminal stent as claimed in claim
2 19 wherein said securing means is bead of thermoplastic
3 material.

1 39. An endoluminal stent as claimed in claim
2 19 wherein the plane of the circumference at each
3 longitudinal end of the stent is square to the
4 longitudinal axis of the stent.

1 40. An endoluminal stent as claimed in claim
2 19 wherein said stent is at least partially covered in
3 fabric.

1 41. An endoluminal stent as claimed in claim
2 31 wherein said wire is nitinol.

1 42. A method of making an endoluminal stent
2 having a plurality of hoops which are axially displaced
3 in a tubular configuration, each of said hoops being
4 formed by a substantially complete turn of a sinuous wire
5 with apices and having a circumference that lies in a
6 plane substantially perpendicular to the longitudinal
7 axis of the stent, said method comprising the steps of:

8 (a) winding a wire in a zig-zag pattern around
9 a mandrel having a plurality of upstanding pins defining
10 said zig-zag pattern to form a first hoop having apices
11 and a circumference that lies in a plane substantially
12 perpendicular to the longitudinal axis of said mandrel;

13 (b) longitudinally displacing said wire with
14 respect to the axis of said mandrel;

15 (c) winding said wire in a zig-zag pattern
16 around a plurality of upstanding pins on said mandrel to
17 form a second hoop, adjacent said first hoop, having
18 apices juxtaposed to the apices of said first
19 circumferential hoop and a circumference that lies in a
20 plane substantially perpendicular to the longitudinal
21 axis of said mandrel;

22 (d) longitudinally displacing said wire with
23 respect to the axis of said mandrel;

24 (e) repeating steps (a)-(d) to form additional
25 hoops until a predetermined number of hoops are formed;

26 (f) annealing said wire on said mandrel;

27 (g) cooling said wire on said mandrel;

28 (h) removing said wire from said mandrel; and

29 (i) securing together at least two juxtaposed
30 apices of adjacent hoops.

1 43. An endoluminal stent comprising a
2 radiopaque marker disposed on at least one end of the
3 stent.

1 44. An endoluminal stent as claimed in claim
2 43 wherein said radiopaque marker comprises a radiopaque
3 element attached to one end of said stent.

1 45. An endoluminal stent as claimed in claim
2 44 wherein said element is a platinum wire.

1 46. An endoluminal stent as claimed in claim
2 44 wherein said element is a gold wire.

1 47. An endoluminal stent as claimed in claim
2 43 wherein said radiopaque marker comprises a radiopaque
3 tube disposed around a part of said stent.

1 48. An endoluminal stent as claimed in claim
2 47 wherein said tube is platinum.

1 49. An endoluminal stent as claimed in claim
2 47 wherein said tube is gold.

1 50. A bifurcated stent for use in
2 juxtaposition with an anatomical bifurcation comprising
3 a proximal stent portion adapted to be disposed within a
4 blood vessel in juxtaposition with a bifurcation, a first
5 distal stent portion adapted to extend across the
6 bifurcation into one of the branched blood vessels, and a
7 second distal stent portion adapted to allow blood to
8 flow from the proximal portion into the other branched
9 vessel and, at least one barb extending radially outward
10 from any of said proximal stent portion, said first
11 distal stent portion, and said second distal stent
12 portion.

1 51. Apparatus for delivering an endoluminal
2 stent or prosthesis into the vasculature comprising:

3 (a) an introducer having a on a distal end
4 thereof; and

5 (b) a cartridge having an inner tubular member
6 containing said stent or prosthesis in a compressed
7 state, an outer sheath, and a second portion of said lock
8 fitting;

9 wherein said first portion of said lock fitting
10 on said introducer mates with said second portion of said
11 lock fitting on said cartridge to prevent relative
12 movement of said introducer and said cartridge.

1 52. Apparatus as claimed in claim 51 wherein
2 said lock fitting is a Luer lock.

1 53. Apparatus as claimed in claim 51 further
2 comprising a hemostasis valve on said introducer and a
3 pusher adapted to push said compressed stent or
4 prosthesis through said cartridge, through said
5 introducer, and into the vasculature.

ABSTRACT

The invention comprises:

5 An introducer for delivering into the
vasculature a straight or bifurcated stent or prosthesis;
a method for delivering into the vasculature a straight
or bifurcated stent or prosthesis; a method of treating
and angeological disease using a bifurcated stent; an
10 endoluminal stent having perpendicular hoop members, each
hoop member formed of wire in a sinuous configuration, at
least some of juxtaposed apices in neighboring hoops
being secured to one another, such stents also forming
axially aligned segments in straight stents, and segments
of bifurcated stents in particular embodiments. Certain
15 embodiments of such stents also include barbs, fabric
covering and radiopaque markers.

FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 3




FIG. 4A




FIG. 4F




FIG. 4E




FIG. 4D




FIG. 4C




FIG. 4B




FIG. 5




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 8E




FIG. 8F




FIG. 8G




FIG. 9




FIG. 10A




FIG. 10B




FIG. 12





FIG. 11







FIG. 15




FIG. 16




FIG. 18




FIG. 17




FIG. 20




FIG. 19




FIG. 21A




FIG. 21B




FIG. 21C




FIG. 22





FIG. 23






FIG. 24B




FIG. 24A

FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 31




FIG. 30




FIG. 34




FIG. 33





FIG. 32



Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am an original, first and joint inventor, of the subject matter which is claimed and for which a patent is sought on the invention entitled BIFURCATED ENDOLUMINAL PROSTHESIS, the specification of which is attached hereto unless the following box is checked:

☒ was filed on June 5, 1995 as United States Application Number 08/463,987 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is not claimed:

Prior Foreign Application(s)

Priority Not Claimed

EP94400284.9

EPO

February 9, 1994

(Number)

(Country)

(Day/Month/Year Filed)

☐

EP94401306.9

EPO

June 10, 1994

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u>08/312,881</u>	<u>09/27/94</u>	<u>Pending</u>
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
<u>08/317,763</u>	<u>10/04/94</u>	<u>Allowed</u>
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)


POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Paul F. Prestia	Reg. No. 23,031	Viviana Amzel	Reg. No. 30,930
Allan Ratner	Reg. No. 19,717	Lawrence E. Ashery	Reg. No. 34,515
Andrew L. Ney	Reg. No. 20,300	Christopher R. Lewis	Reg. No. 36,201
Kenneth N. Nigon	Reg. No. 31,549	Steven E. Koffs	Reg. No. 37,163
Kevin R. Casey	Reg. No. 32,117	Anthony L. DiBartolomeo	Reg. No. 37,308
Guy T. Donatiello	Reg. No. 33,167	Allan M. Wheatcraft	Reg. No. 36,307
Benjamin E. Leace	Reg. No. 33,412	Anthony Grillo	Reg. No. 36,535
James C. Simmons	Reg. No. 24,842	Leon Nigohosian, Jr.	Reg. No. 39,791

Address all correspondence to: Paul F. Prestia
Ratner & Prestia, Suite 301, One Westlakes, Berwyn, P.O. Box 980, Valley Forge, PA 19482-0980
 Address all telephone calls to: Paul F. Prestia at (610) 407-0700.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name and address of joint inventor signing this copy of declaration (given name, family name) George Goicoechea

First inventor's signature  Date 9/12/97
 Residence P.O. Box F-44289, Freeport, Grand Bahama, Bahamas
 Citizenship United States
 Post Office Address P.O. Box F-44289, Freeport, Grand Bahama
Bahamas

Full name and address of additional joint inventor (given name, family name) Claude Mialhe
 Residence Av. Pierre Brossolette, 83300 Draguignan, France
 Citizenship France
 Post Office Address Av. Pierre Brossolette, 83300 Draguignan,
France



Additional inventors are being named on separately numbered sheets attached hereto.

Full name and address of additional joint inventor (given name, family name) John Hudson

Residence 1A Salcombe Drive, Glenfield, Leicester LE3 8AG, ENGLAND

Citizenship United Kingdom

Post Office Address 1A Salcombe Drive

Glenfield,

Leicester LE3 8AG

ENGLAND

Full name and address of additional joint inventor (given name, family name) Andrew H. Cragg

Residence 4502 Edina Boulevard, Edina, Minnesota 55424

Citizenship United States

Post Office Address 4502 Edina Boulevard

Edina, Minnesota 55424

Full name and address of additional joint inventor (given name, family name) Michael D. Dake

Residence 665 Gerona Road, Stanford, California 94305

Citizenship United States

Post Office Address 665 Gerona Road

Stanford, California 94305

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am an original, first and joint inventor, of the subject matter which is claimed and for which a patent is sought on the invention entitled BIFURCATED ENDOLUMINAL PROSTHESIS, the specification of which is attached hereto unless the following box is checked:

☒ was filed on June 5, 1995 as United States Application Number 08/463,987 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is not claimed:

Prior Foreign Application(s)

Priority Not Claimed

EP94400284.9

EPO

February 9, 1994

(Number)

(Country)

(Day/Month/Year Filed)

☐

EP94401306.9

EPO

June 10, 1994

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

08/312,881

(Application Number)

09/27/94

(Filing Date)

Pending

(Status - patented, pending, abandoned)

08/317,763

(Application Number)

10/04/94

(Filing Date)

Allowed

(Status - patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Paul F. Prestia	Reg. No. 23,031	Viviana Amzel	Reg. No. 30,930
Allan Ratner	Reg. No. 19,717	Lawrence E. Ashery	Reg. No. 34,515
Andrew L. Ney	Reg. No. 20,300	Christopher R. Lewis	Reg. No. 36,201
Kenneth N. Nigon	Reg. No. 31,549	Steven E. Koffs	Reg. No. 37,163
Kevin R. Casey	Reg. No. 32,117	Anthony L. DiBartolomeo	Reg. No. 37,308
Guy T. Donatiello	Reg. No. 33,167	Allan M. Wheatcraft	Reg. No. 36,307
Benjamin E. Leace	Reg. No. 33,412	Anthony Grillo	Reg. No. 36,535
James C. Simmons	Reg. No. 24,842	Leon Nigohosian, Jr.	Reg. No. 39,791

Address all correspondence to: Paul F. Prestia

Ratner & Prestia, Suite 301, One Westlakes, Berwyn, P.O. Box 980, Valley Forge, PA 19482-0980

Address all telephone calls to: Paul F. Prestia at (610) 407-0700.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name and address of joint inventor signing this copy of declaration (given name, family name) Michael D. Dake

First Inventor's signature Michael D. Dake Date January 8, 1997

Residence 665 Gerona Road, Stanford, California 94305

Citizenship United States

Post Office Address 665 Gerona Road
Stanford, California 94305

Full name and address of additional joint inventor (given name, family name) George Goicoechea

Residence P.O. Box F-44289, Freeport, Grand Bahama, Bahamas

Citizenship United States

Post Office Address P.O. Box F-44289, Freeport, Grand Bahama
Bahamas

☒ Additional inventors are being named on separately numbered sheets attached hereto.

Full name and address of additional joint inventor (given name, family name) Claude Mialhe

Residence Av. Pierre Brossolette, 83300 Draquignan, France

Citizenship France

Post Office Address Av. Pierre Brossolette, 83300 Draquignan,

France

Full name and address of additional joint inventor (given name, family name) John Hudson

Residence 1A Salcombe Drive, Glenfield, Leicester LE3 8AG, ENGLAND

Citizenship United Kingdom

Post Office Address 1A Salcombe Drive

Glenfield,

Leicester LE3 8AG

ENGLAND

Full name and address of additional joint inventor (given name, family name) Andrew H. Cragg

Residence 4502 Edina Boulevard, Edina, Minnesota 55424

Citizenship United States

Post Office Address 4502 Edina Boulevard

Edina, Minnesota 55424

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am an original, first and joint inventor, of the subject matter which is claimed and for which a patent is sought on the invention entitled BIFURCATED ENDOLUMINAL PROSTHESIS, the specification of which is attached hereto unless the following box is checked:

☒ was filed on June 5, 1995 as United States Application Number 08/463,987 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is not claimed:

Prior Foreign Application(s)

Priority Not Claimed

EP94400284.9 EPO February 9, 1994

(Number) (Country) (Day/Month/Year Filed)

☐

EP94401306.9 EPO June 10, 1994

(Number) (Country) (Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number) (Filing Date)

(Application Number) (Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u>08/312,881</u>	<u>09/27/94</u>	<u>Pending</u>
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
<u>08/317,763</u>	<u>10/04/94</u>	<u>Allowed</u>
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Paul F. Prestia	Reg. No. 23,031	Viviana Amzel	Reg. No. 30,930
Allan Ratner	Reg. No. 19,717	Lawrence E. Ashery	Reg. No. 34,515
Andrew L. Ney	Reg. No. 20,300	Christopher R. Lewis	Reg. No. 36,201
Kenneth N. Nigon	Reg. No. 31,549	Steven E. Koffs	Reg. No. 37,163
Kevin R. Casey	Reg. No. 32,117	Anthony L. DiBartolomeo	Reg. No. 37,308
Guy T. Donatiello	Reg. No. 33,167	Allan M. Wheatcraft	Reg. No. 36,307
Benjamin E. Leace	Reg. No. 33,412	Anthony Grillo	Reg. No. 36,535
James C. Simmons	Reg. No. 24,842	Leon Nigohosian, Jr.	Reg. No. 39,791

Address all correspondence to: Paul F. Prestia
Ratner & Prestia, Suite 301, One Westlakes, Berwyn, P.O. Box 980, Valley Forge, PA 19482-0980
 Address all telephone calls to: Paul F. Prestia at (610) 407-0700.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name and address of joint inventor signing this copy of declaration (given name, family name) John Hudson

First inventor's signature  Date 11-Jan-97

Residence 1A Salcombe Drive, Glenfield, Leicester LE3 8AG, ENGLAND

Citizenship United Kingdom

Post Office Address 1A Salcombe Drive

Glenfield,

Leicester LE3 8AG

ENGLAND

Full name and address of additional joint inventor (given name, family name) George Goicoechea

Residence P.O. Box F-44289, Freeport, Grand Bahama, Bahamas

Citizenship United States

Post Office Address P.O. Box F-44289, Freeport, Grand Bahama

Bahamas



Additional inventors are being named on separately numbered sheets attached hereto.

Full name and address of additional joint inventor (given name, family name) Claude Mialhe

Residence Av. Pierre Brossolette, 83300 Draquignan, France

Citizenship France

Post Office Address Av. Pierre Brossolette, 83300 Draquignan,
France

Full name and address of additional joint inventor (given name, family name) Andrew H. Cragg

Residence 4502 Edina Boulevard, Edina, Minnesota 55424

Citizenship United States

Post Office Address 4502 Edina Boulevard
Edina, Minnesota 55424

Full name and address of additional joint inventor (given name, family name) Michael D. Dake

Residence 665 Gerona Road, Stanford, California 94305

Citizenship United States

Post Office Address 665 Gerona Road
Stanford, California 94305

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am an original, first and joint inventor, of the subject matter which is claimed and for which a patent is sought on the invention entitled BIFURCATED ENDOLUMINAL PROSTHESIS, the specification of which is attached hereto unless the following box is checked:

☒ was filed on June 5, 1995 as United States Application Number 08/463,987 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is not claimed:

Prior Foreign Application(s)

Priority Not Claimed

EP94400284.9 EPO February 9, 1994

(Number) (Country) (Day/Month/Year Filed) ☐

EP94401306.9 EPO June 10, 1994

(Number) (Country) (Day/Month/Year Filed) ☐

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number) (Filing Date)

(Application Number) (Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u>08/312,881</u>	<u>09/27/94</u>	<u>Pending</u>
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
<u>08/317,763</u>	<u>10/04/94</u>	<u>Allowed</u>
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Paul F. Prestia	Reg. No. 23,031	Viviana Amzel	Reg. No. 30,930
Allan Ratner	Reg. No. 19,717	Lawrence E. Ashery	Reg. No. 34,515
Andrew L. Ney	Reg. No. 20,300	Christopher R. Lewis	Reg. No. 36,201
Kenneth N. Nigon	Reg. No. 31,549	Steven E. Koffs	Reg. No. 37,163
Kevin R. Casey	Reg. No. 32,117	Anthony L. DiBartolomeo	Reg. No. 37,308
Guy T. Donatiello	Reg. No. 33,167	Allan M. Wheatcraft	Reg. No. 36,307
Benjamin E. Leace	Reg. No. 33,412	Anthony Grillo	Reg. No. 36,535
James C. Simmons	Reg. No. 24,842	Leon Nigohosian, Jr.	Reg. No. 39,791

Address all correspondence to: Paul F. Prestia
Ratner & Prestia, Suite 301, One Westlakes, Berwyn, P.O. Box 980, Valley Forge, PA 19482-0980

Address all telephone calls to: Paul F. Prestia at (610) 407-0700.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name and address of joint inventor signing this copy of declaration (given name, family name) Andrew H. Cragg

First inventor's signature  Date 1.8.97

Residence 4502 Edina Boulevard, Edina, Minnesota 55424

Citizenship United States

Post Office Address 4502 Edina Boulevard

Edina, Minnesota 55424

Full name and address of additional joint inventor (given name, family name) George Goicoechea

Residence P.O. Box F-44289, Freeport, Grand Bahama, Bahamas

Citizenship United States

Post Office Address P.O. Box F-44289, Freeport, Grand Bahama

Bahamas



Additional inventors are being named on separately numbered sheets attached hereto.

Full name and address of additional joint inventor (given name, family name) Claude Mialhe

Residence Av. Pierre Brossolette, 83300 Draguignan, France

Citizenship France

Post Office Address Av. Pierre Brossolette, 83300 Draguignan,

France

Full name and address of additional joint inventor (given name, family name) John Hudson

Residence 1A Salcombe Drive, Glenfield, Leicester LE3 8AG, ENGLAND

Citizenship United Kingdom

Post Office Address 1A Salcombe Drive

Glenfield,

Leicester LE3 8AG

ENGLAND

Full name and address of additional joint inventor (given name, family name) Michael D. Dake

Residence 665 Gerona Road, Stanford, California 94305

Citizenship United States

Post Office Address 665 Gerona Road

Stanford, California 94305

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am an original, first and joint inventor, of the subject matter which is claimed and for which a patent is sought on the invention entitled BIFURCATED ENDOLUMINAL PROSTHESIS, the specification of which is attached hereto unless the following box is checked:

☒ was filed on June 5, 1995 as United States Application Number 08/463,987 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is not claimed:

Prior Foreign Application(s)

Priority Not Claimed

EP94400284.9

EPO

February 9, 1994

(Number)

(Country)

(Day/Month/Year Filed)

☐

EP94401306.9

EPO

June 10, 1994

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

08/312.88109/27/94Pending

(Application Number)

(Filing Date)

(Status - patented, pending, abandoned)

08/317.76310/04/94Allowed

(Application Number)

(Filing Date)

(Status - patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Paul F. Prestia	Reg. No. 23,031	Viviana Amzel	Reg. No. 30,930
Allan Ratner	Reg. No. 19,717	Lawrence E. Ashery	Reg. No. 34,515
Andrew L. Ney	Reg. No. 20,300	Christopher R. Lewis	Reg. No. 36,201
Kenneth N. Nigon	Reg. No. 31,549	Steven E. Koffs	Reg. No. 37,163
Kevin R. Casey	Reg. No. 32,117	Anthony L. DiBartolomeo	Reg. No. 37,308
Guy T. Donatiello	Reg. No. 33,167	Allan M. Wheatcraft	Reg. No. 36,307
Benjamin E. Leace	Reg. No. 33,412	Anthony Grillo	Reg. No. 36,535
James C. Simmons	Reg. No. 24,842	Leon Nigohosian, Jr.	Reg. No. 39,791

Address all correspondence to: Paul F. Prestia
Ratner & Prestia, Suite 301, One Westlakes, Berwyn, P.O. Box 980, Valley Forge, PA 19482-0980
 Address all telephone calls to: Paul F. Prestia at (610) 407-0700.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name and address of joint inventor signing this copy of declaration (given name, family name) Claude Mialhe

First inventor's signature

Date

Residence Av. Pierre Brossolette, 83300 Draguignan, FranceCitizenship FrancePost Office Address Av. Pierre Brossolette, 83300 Draguignan,France

Full name and address of additional joint inventor (given name, family name) George Goicoechea

Residence P.O. Box F-44289, Freeport, Grand Bahama, BahamasCitizenship United StatesPost Office Address P.O. Box F-44289, Freeport, Grand BahamaBahamas

Additional inventors are being named on separately numbered sheets attached hereto.

Full name and address of additional joint inventor (given name, family name) John Hudson

Residence 1A Salcombe Drive, Glenfield, Leicester LE3 8AG, ENGLAND

Citizenship United Kingdom

Post Office Address 1A Salcombe Drive

Glenfield,

Leicester LE3 8AG

ENGLAND

Full name and address of additional joint inventor (given name, family name) Andrew H. Cragg

Residence 4502 Edina Boulevard, Edina, Minnesota 55424

Citizenship United States

Post Office Address 4502 Edina Boulevard

Edina, Minnesota 55424

Full name and address of additional joint inventor (given name, family name) Michael D. Dake

Residence 665 Gerona Road, Stanford, California 94305

Citizenship United States

Post Office Address 665 Gerona Road

Stanford, California 94305

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: George Goicoechea et al. : Art Unit: To Be Assigned
Serial No.: To Be Assigned : Examiner: To Be Assigned
Filed: Herewith :
FOR: BIFURCATED ENDOLUMINAL :
PROSTHESIS


DELETION OF INVENTORS, 1.63(d)(2)

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R :

Pursuant to 37 C.F.R. § 1.63(d)(2), this application is being filed by fewer than all the inventors named in the prior application from which benefit is claimed under 35 U.S.C. § 120. Please delete the following inventor(s) named in the prior nonprovisional application: Claude Mialhe and Michael D. Dake.

Respectfully submitted,




Paul F. Prestia, Reg. No. 23,031
Joshua L. Cohen, Reg. No. 38,040
Attorneys for Applicants

Suite 301
One Westlakes, Berwyn
P.O. Box 980
Valley Forge, PA 19482-0980
(610) 407-0700

The Assistant Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. 18-0350 of any fees associated with this communication.

EXPRESS MAIL Mailing Label Number: EL370858037US
Date of Deposit: August 31, 1999

I hereby certify that this paper and fee are being deposited, under 37 C.F.R. § 1.10 and with sufficient postage, using the "Express Mail Post Office to Addressee" service of the United States Postal Service on the date indicated above and that the deposit is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Kathleen Libby